The Dirty Secret of Longevity: The Basics Aren’t Done, But the Drips Are Flowing

Are we building a longevity industry on experimental tools for people who never got a real foundation?

This is an educational, strategic perspective, not personal medical advice. Discuss any changes with your clinician. Visuals in this article were created with Nano Banana, from my original longevity stack and evidence ladder models.

---

This article started as a shopping list.

I sat down to plan the diagnostics and “frontier tools” for the longevity project I’m building in Portugal. The list was long: devices, chambers, protocols, drips. On paper, it looked like a greatest-hits compilation of the current longevity scene.

Then I took that list to my medical advisory board.

Item by item, we went through it.
Item by item, I saw the same expression:

• “Interesting mechanism… but for whom?”

• “This is promising… but based on what level of evidence?”

• “Would you really offer this before you’ve fixed blood pressure, sleep, strength?”

I realised something uncomfortable:

I was the founder, the one supposed to design the ethical, evidence-based version of this space – and even I had quietly bought the marketing story before I understood the reality.

If I can fall for the polished narrative while staring at a capex spreadsheet, what chance does a time-poor, health-anxious client have?

That conversation sent me back to first principles:
What actually helps? What belongs where? What does an honest longevity stack look like?

This piece is my attempt to answer that – partly for myself as an operator, and partly for anyone who’s ever been handed a glossy menu of “longevity” options and felt a quiet unease they couldn’t name.

---

I also keep meeting the same person in different cities.

Mid-40s to late-50s. Successful. Time-poor, health-anxious, “optimisation-curious”. Multiple wearables. Has worn a continuous glucose monitor at least once. A growing folder of lab results and “longevity panels”.

They can quote their resting heart rate, HRV, step count, and “deep sleep minutes” on command. They’ve even done a few “full workups”.

What they don’t have is a serious, joined-up conversation about what all of this should add up to in terms of blood pressure, strength, aerobic capacity, and week-by-week behaviour — or where, in that picture, drips and other frontier tools genuinely belong.

If that’s you — or you’re building or backing a clinic selling to that person — this is who I’m writing for.

Walk through any major city and you’ll see the new pantheon of “longevity”:

• Marble-floored clinics

• Biomarker labs

• Full-body MRI suites

• Peptide bars

• Hyperbaric pods

• “Cellular reset” IV lounges

The implicit promise: if you can afford the frontier tools, you can skip straight to advanced optimisation.

Some of this is genuine progress. Preventive care is finally socially acceptable. Our understanding of metabolism, inflammation, and ageing biology is far beyond “eat less, move more”.

But underneath the chrome sits a simple, uncomfortable reality:

There is a widening gap between what people believe they are buying and what science can actually prove.

To navigate that gap, you don’t need to become a biochemist. You need two mental models:

• the Three-Floor Longevity Stack — how care should be sequenced

• the Longevity Evidence Ladder — how strong the proof really is

Everything else is commentary.

---

The Three-Floor Longevity Stack

If I had to sketch responsible longevity care on a whiteboard, it would look like a three-floor building.

Floor 1 — Foundations (Behavioural & Physiological)

The boring, powerful fundamentals with the strongest long-term human data:

• Muscle mass and strength

• Cardiorespiratory fitness

• Blood pressure, glucose, and lipids under control

• Sleep and circadian stability

• Low smoking and heavy drinking

• Meaningful, stable relationships and reduced isolation

Floor 2 — Structured Medical Prevention

Conventional medicine used proactively and intelligently:

• Appropriate screening and imaging

• Evidence-based management of hypertension, lipids, and diabetes risk

• Targeted use of established drugs where they change outcomes

• Basic nutritional and psychological support woven into care

Floor 3 — Frontier Tools

The experimental, story-rich layer with more uncertainty and more risk:

• IV “longevity” drips

• NAD⁺ infusions and precursors

• Hyperbaric oxygen therapy (HBOT) for “anti-ageing”

• Grey-zone injectable peptides

• Plasma exchange and “blood cleansing”

In a sane system, people climb in order: Floor 1 → Floor 2 → Floor 3.

In the pitch decks and shopping lists (including my first one), the order is often reversed.

If your clinic doesn’t touch your blood pressure, sleep, and strength before it touches a drip, it’s not doing longevity — it’s doing theatre.

Call that the minimum viable standard for longevity care: blood pressure, sleep, and strength before drips.

That’s the line most of the sector is quietly crossing.

---

The Longevity Evidence Ladder: Mechanism → Biomarker → Outcome

The second model is the Longevity Evidence Ladder. Whenever you hear a longevity claim, ask: on which rung are we?

1. Mechanism
   Something interesting happens in a cell or pathway — often in animals or a petri dish.

“This molecule activates this pathway in mice.”

1. Biomarker
   A lab value or imaging metric moves in a direction we assume is good.

“This protocol lengthened telomeres in blood cells.”

1. Outcome
   Human beings live longer, stay independent longer, or avoid major disease more often over meaningful time.

“Lower cardiovascular events; better survival; more functional years.”

Most frontier tools live on rung 1 or 2.
Most marketing (and my original equipment list) treated them as if they were safely on rung 3.

If a claim never climbs past mechanisms and biomarkers, it doesn’t get to wear an outcome halo.

Using tools on rung 1 or 2 isn’t inherently unethical. Charging outcome-level prices and making outcome-level promises when you only have mechanism and biomarkers is.

---

Five Questions to Ask Any Longevity Clinic Before You Buy Anything

These questions simply combine the Stack and the Ladder into something you can use in a consultation.

When someone offers you a “longevity” intervention, ask:

1. “Which rung of the Evidence Ladder are we on — mechanism, biomarker, or outcome?”

2. “Which floor of the Longevity Stack is this — foundation, medical prevention, or frontier?”

3. “If this tool didn’t exist, what would you recommend I do instead to improve my long-term risk?”

4. “What are the main risks or downsides, in plain language, for someone like me?”

5. “How will we know it worked, and when would we stop?”

A credible operator will not be threatened by these questions. If they look vague or defensive, the problem is not your curiosity.

From here, notice how the same pattern repeats: strong story, mechanistic promise, weak outcome proof — and mis-targeting to people whose Floor 1 is not yet in order.

---

I. IV Drips: Clinical Tool, Lifestyle Illusion

Marketing promises: “Immune boost”, “Detox”, “Cellular repair.”
Evidence tier: Strong outcome-level evidence in hospitals (dehydration, malnutrition); minimal evidence for longevity in otherwise healthy people.

IV therapy is lifesaving in emergency and inpatient medicine. That clearly belongs on Floor 2.

For a generally healthy person walking into an IV lounge “for longevity”, the story is different. There is no robust long-term data showing that routine vitamin drips in people with normal intake and absorption extend lifespan or healthspan.

A specific red flag: IV iron

Iron infusions are essential when someone is truly iron-deficient and cannot correct it orally. But “elective” IV iron in non-deficient people is not a harmless upgrade.

Free iron can drive the Fenton reaction — reacting with hydrogen peroxide to generate highly reactive radicals that damage cells and tissues. You may be paying for a “detox” while quietly increasing oxidative stress in the organs you are trying to protect.

If you have:

• documented deficiency

• appropriate work-up

• a clear indication

…an iron infusion in a medical setting can be appropriate. For the average tired executive with normal labs, it is risk without proven long-term upside.

If someone suggests an IV drip for “longevity”, ask:

• “Which deficiency are you correcting, and can I see that in my labs?”

• “Do you still recommend this if my levels are normal?”

• “Beyond feeling better today, what long-term outcome are you expecting — and based on what evidence?”

Different tool, same pattern: clinical value in Floor 2, promises on Floor 3, sold to people with half-built Floor 1.

---

II. NAD⁺: The Biomarker That Became a Promise

Marketing promises: “Mitochondrial reset”, “Youth drip”, “Brain reboot.”
Evidence tier: Strong mechanistic and animal data; early and mixed human data; no long-term outcome data in healthy adults.

NAD⁺ is central to energy metabolism and DNA repair. Levels of NAD⁺-related pathways do appear to change with age in specific tissues. That’s the mechanistic story.

Short-term human studies show that infusions or precursors can raise NAD⁺ levels or shift metabolic markers. That’s the biomarker story.

What we do not yet have is convincing, long-term outcome data showing that aggressively boosting NAD⁺ in otherwise healthy adults clearly extends life or reduces major disease events.

The acute reaction no one markets

Fast NAD⁺ infusions commonly cause intense discomfort: chest tightness, abdominal cramping, a sense of “impending doom”. This is likely linked to smooth muscle activation as the infusion hits the system rapidly.

For an already optimised individual who understands that this is an experimental, marginal bet, that may be acceptable. For someone who smokes, sleeps five hours, doesn’t exercise, and is trying to “buy more time”, it is a poor use of risk and capital.

Calling this “reversing ageing” because a metabolite moved on a blood test is not optimism; it’s marketing inflation.

If a clinic proposes NAD⁺, ask:

• “Is the evidence here mainly mechanistic/biomarker-level, or do you have outcome data in people like me?”

• “What proportion of your clients experience acute side-effects, and how do you manage them?”

• “If I skip NAD⁺, what are the top three things you would prioritise instead to change my long-term risk?”

---

III. Hyperbaric Oxygen (HBOT): Real Medicine, Overstretched Story

Marketing promises: “Reversed biological age”, “Regeneration.”
Evidence tier: Strong outcome-level data for specific conditions; early biomarker-level data for “ageing”; no direct lifespan data.

HBOT is not pseudoscience. It is standard of care for decompression sickness, certain non-healing wounds, and a few other well-defined indications. That is Floor 2 medicine.

The longevity hype leans heavily on early protocols where structured HBOT increased telomere length and reduced senescent immune cells in older adults. These are biomarker shifts — interesting, but not the same as “you are now younger”. Changing telomere length in one blood cell population does not automatically mean you have reversed ageing across an entire human being.

The unglamorous risks

• Pressure-related injuries to ears and sinuses

• Risk of seizures at high exposures

• Fire risk in oxygen-rich environments, especially outside hospital-grade setups

In a tightly controlled medical environment, for a well-selected person who already has strong foundations, HBOT may be a reasonable experiment. In a strip-mall chamber sold as “reverse your age in 10 sessions”, it is being marketed far beyond its proof.

If you are offered HBOT “for longevity”, ask:

• “Is my use case one of the established medical indications, or is this experimental?”

• “What non-trivial risks apply at the pressures and protocol you use here?”

• “What specific changes — beyond a glossy report — would count as meaningful success?”

Again: mechanisms and biomarkers on Floor 3, sold to people who haven’t yet earned Floor 1.

---

IV. Peptides: Pharmacology Without Guardrails

Marketing promises: “Cellular rejuvenation”, “Fat loss”, “Optimised hormones.”
Evidence tier: Ranges from fully approved drugs with strong trial data to research chemicals with almost no human safety data.

At one end of the spectrum, we have drugs like GLP-1 agonists with large, regulated trials and clear indications.

At the other, we have compounds such as BPC-157, CJC-1295, TB-500 and others, often sold as “research peptides” or “not for human use” while being marketed informally for exactly that.

Because these often sit outside normal pharmaceutical channels, they can escape standard quality controls. Independent testing and regulatory alerts have found:

• Mislabelled vials

• Impurities and incomplete peptide chains

• Microbial contamination and endotoxins

• Vials whose contents do not match the label at all

You end up with a paradox: drug-like effects without drug-level oversight.

In a formal medical program or clinical trial, with real sourcing and monitoring, certain peptides may be worth exploring for a well-optimised person. Buying them from an online reseller because a podcast said “this heals everything” is a different proposition entirely.

Before touching peptides, ask:

• “Is this an approved drug for my indication, or a research-grade product?”

• “Who manufactures this, and under which quality standards?”

• “How will you monitor benefits and side-effects over time — and what would make you stop?”

---

V. Plasma Exchange and “Blood Cleansing”: Big Procedure, Small Proof

Marketing promises: “Microplastic removal”, “Immune rejuvenation”, “Next frontier.”
Evidence tier: Strong outcome-level data for specific autoimmune and blood disorders; mechanistic speculation for longevity in healthy adults; no proven lifespan or healthspan benefit in that group.

Therapeutic plasma exchange (TPE) is a real hospital therapy. In certain autoimmune and haematologic conditions, it can be life-saving. That is legitimate Floor 2 medicine.

The longevity narrative leans on two ideas:

• Diluting “pro-ageing” factors in the blood

• Physically removing microplastics or other contaminants

Mechanistically, these are plausible hypotheses. They are simply not yet supported by clear human outcome data in otherwise healthy people.

The practical irony

The extracorporeal circuits used for “blood cleansing” are made of plastics that can themselves leach plasticisers. You undergo an invasive, resource-intensive procedure, with vascular and bleeding risks, for a longevity benefit that remains theoretical.

If someone pitches plasma exchange “for longevity”, ask:

• “What specific diagnosis or risk are we treating, in my case?”

• “What human outcome data exists in people like me — not in mice, not in theory?”

• “How do you weigh the procedural risks against that, and who would you advise not to do this?”

Different machine, same pattern: heavy hardware, light outcomes, sold as if it were rung 3.

---

The Uncomfortable Truth: The Boring Stuff Wins

Why does the industry lean so heavily on expensive, theoretical technologies?

Because the interventions that actually move long-term outcomes are hard to package and hard to monetise.

When you zoom out to large human datasets — decades-long cohorts tracking people over time — a different picture emerges. Simple, unglamorous capacities and behaviours show up again and again as associated with lower mortality and disability. For example, long-running Finnish work on sauna use shows lower cardiovascular and all-cause mortality in people who do something as mundane as sit in a hot room regularly. Not because sauna is magic, but because simple, repeatable behaviours compound.

Across the literature, the most robust drivers of healthy longevity look suspiciously like Floor 1:

• Maintaining muscle mass and strength

• Building and preserving cardiorespiratory fitness

• Keeping blood pressure, glucose, and lipids within healthy ranges

• Protecting sleep and circadian rhythm

• Reducing smoking and heavy drinking

• Staying embedded in real, not performative, relationships

These fundamentals don’t photograph well. They don’t fit neatly into a weekend retreat. Margins are lower. But they are the engine.

For the vast majority of people, frontier longevity tools are not “advanced optimisation” — they are a detour around the only interventions with proven impact.

The small minority who might reasonably consider experimental tools are usually those who have already:

• Lifted consistently for years

• Built meaningful aerobic capacity

• Normalised their metabolic markers

• Stabilised their sleep

• Removed obvious toxins like smoking and heavy nightly drinking

• Put some basic order into their psychological and relational life

They are playing for marginal gains at the edge. Many others are being sold the edge as a starting line.

If that sounds blunt, good. Longevity should be.

---

If You’re Actually in the Optimised Minority

If you can honestly say you:

• train with resistance and aerobic work most weeks, for years

• have stable, well-controlled metabolic markers

• sleep 7–9 hours on a reasonably consistent schedule

• don’t smoke, and don’t sedate yourself with alcohol every evening

• have at least a basic grip on stress and relationships

…then you are closer to the group for whom frontier tools might be considered as experimental, marginal bets.

If that’s you, a more honest way to think about the frontier is:

1. Treat frontier tools as “risk-budget spending”, not necessities.
   Assume the real compounding still comes from your foundations. Drips, chambers, peptides, and exchange circuits are things you spend a clearly defined risk and money budget on — not the core of your strategy.

2. Demand to know exactly which rung you’re on.
   For every tool: is the evidence mainly mechanistic, biomarker-level, or outcome-level? If a tool never climbs past mechanism and biomarkers, treat it accordingly.

3. Insist on medical-grade process, not vibes.
   Real clinicians. Written protocols. Dosing, monitoring, and specific stop criteria: “We stop if X happens or if we don’t see Y by time Z.”

4. Be explicit about your motivation.
   Curiosity and optimisation are legitimate motivations. Just don’t pretend a mechanistic experiment is a guaranteed longevity dividend. Naming your motive keeps you and your clinician on the ethical side of the line.

Frontier tools are not automatically unethical. Used transparently, on top of a well-built foundation, with a clear risk budget, they can be explored as optional upside.

The ethical failure happens when they are sold as foundations to people who do not yet have one.

---

If Your Clinic Can’t Do at Least This, It’s Not in the Longevity Business Yet

This is where the conversation needs to go next. Less “are drips good or bad?” and more “what does a defensible model look like?”

A responsible longevity operator would:

• Sequence care by floors.
  Every client starts on Floor 1. Floor 3 tools are not routinely offered until key basics — strength or a fitness proxy, blood pressure, glucose, lipids, sleep — are at least being measured and actively addressed.

• Map every tool onto the Longevity Evidence Ladder in writing.
  For each intervention, there is a short, client-facing summary: what is known (outcomes), what is promising (biomarkers), what is still theoretical (mechanisms).

• Define eligibility and exclusion criteria for frontier tools.
  Not everyone gets everything. Some tools are explicitly reserved for people who have cleared certain basics or meet clear clinical criteria.

• Track outcomes beyond “felt great after the session”.
  Strength, fitness, metabolic markers, sleep measures, functional capacity — followed over years, not weeks, alongside any frontier interventions.

• Disclose risk with the same boldness as promise.
  Oxidative stress from iron, contamination risks in grey-zone peptides, barotrauma and fire risk in HBOT, vascular risks in plasma exchange — on the table, not in the fine print.

If your “longevity clinic” leads with drips and never measures your strength, it is not a longevity clinic. It is a day spa with syringes.

Clinics that get this right will also be the more durable businesses: lower regulatory risk, fewer angry ex-clients, and a compounding data asset on what actually moves outcomes. In jurisdictions like the EU, and countries like Portugal where medical regulation is already strict and likely to tighten further, building as if Floors 1 and 2 are mandatory is not idealism; it’s risk management.

In a mature sector, regulators will eventually demand this kind of sequencing and transparency. The only real question is who chooses to behave as if that future already exists.

---

The Business Line No One Talks About

Right now, the longevity marketplace thrives on two confusions:

• Blurring mechanisms and biomarkers into implied outcomes

• Treating optimised edge cases and average, under-served clients as if they should be sold the same tools

We don’t need less innovation. We need more honesty about two things:

1. Where each tool really sits on the Longevity Evidence Ladder.

2. Which floor of the Longevity Stack, and which type of person, it is genuinely appropriate for.

We have normalised selling the feeling of safety to people who are actually buying structured uncertainty — when many of them should first be offered sleep, strength, and glucose control.

That meeting with my advisory board – the doubtful looks at my shopping list – was the best kind of humiliation: the kind that forces you to rebuild your model from the ground up.

Innovation will shape the future of preventive medicine. But in longevity, the scarce resource is not another device, molecule, or chamber. It is trust — earned by telling people not just what you offer, but whether they are the kind of person who should be offered it at all.

The venture I am building, and this publication, will live on that line: optimistic about breakthroughs, ruthless about shortcuts, and committed to a simple rule:

If your blood pressure, sleep, and strength haven’t been touched, your drips can wait.

I wrote this first to correct my own thinking. I’m sharing it so you don’t have to pay as much tuition to the marketing machine as I did.

---